Physician profile
Viktoras Palys
NPI 1922311315
$14,064.39
in general payments reported to CMS, 2019-2025
14 companies · $106 in 2025
The $106 reported for 2025 was less than what a typical Neurological Surgery provider received nationally (typical 2025 total: $604).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,204 · 2021: $2,175 · 2022: $2,492 · 2023: $3,203 · 2024: $3,885 · 2025: $106.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $5,452 · Food and Beverage: $1,742.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $5,452.31 |
| Food and Beverage | $1,741.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neuropace, INC. | $4,592.02 | 2022-2024 | |
| Globus Medical, INC. | $2,387.55 | 2022 | |
| Medtronic, INC. | $2,224.50 | 2021-2025 | Mazor X System, Stealthstation S8 Platform |
| Medtronic USA, INC. | $1,246.66 | 2019 | |
| Monteris Medical Corporation | $1,045.38 | 2019-2023 | Neuroblate |
| Arthrex, INC. | $1,008.70 | 2024 | |
| Centinel Spine, LLC | $729.95 | 2023 | Prodisc C Vivo |
| Brainlab, INC. | $406.96 | 2024 | Surgical Planning and Navigation Radiation Treatment Planning and Positioning |
| Davol INC. | $140.77 | 2023 | Avitene Ultrafoam |
| Boston Scientific Corporation | $105.38 | 2023 | Wavewriter Alpha Prime 16 |
| Acadia Pharmaceuticals INC | $56.59 | 2025 | Daybue |
| Si-Bone, INC. | $44.60 | 2019 | |
| Stryker Corporation | $39.11 | 2023 | Spinejack |
| Zimmer Biomet Holdings, INC. | $36.22 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Viktoras Palys listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.